Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018.
The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.
Much conversation and research were going on over a couple of years on a new class of drug- CGRP inhibitors and its potential to prevent and treat a migraine.
The US FDA has approved the first treatment- Aimovig (erenumab-aooe) to prevent migraine in adults, belonging to the new class of drug called CGRP inhibitors. Aimovig is developed by Amgen.
Read the article to know about Aimovig and developments in the popular area of migraine research- CGRP inhibitors.
Indian Institute of Technology Roorkee (IIT Roorkee) scientists have developed an improved orthopedic implant technology for sustained drug release. Currently, the technology is with the company, Biotech Consortium India Limited (BCIL) for transfer, for the commercialization of the technology.
First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.
Within first four months of 2018, seven new drugs are already approved by the FDA for a wide range of diseases including HIV, psoriasis, and rare cancers. 2018 will also see the first ever “game-changing” CRISPR gene editing clinical trial in humans.